JP2003511087A - ニューロンの活性を調節する化合物を同定する方法 - Google Patents

ニューロンの活性を調節する化合物を同定する方法

Info

Publication number
JP2003511087A
JP2003511087A JP2001530589A JP2001530589A JP2003511087A JP 2003511087 A JP2003511087 A JP 2003511087A JP 2001530589 A JP2001530589 A JP 2001530589A JP 2001530589 A JP2001530589 A JP 2001530589A JP 2003511087 A JP2003511087 A JP 2003511087A
Authority
JP
Japan
Prior art keywords
peptide
sequence
plmf
amino acids
syntaxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001530589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511087A5 (https=
Inventor
テランス ピー． スナッチ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JP2003511087A publication Critical patent/JP2003511087A/ja
Publication of JP2003511087A5 publication Critical patent/JP2003511087A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001530589A 1999-10-13 2000-10-13 ニューロンの活性を調節する化合物を同定する方法 Pending JP2003511087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15909599P 1999-10-13 1999-10-13
US60/159,095 1999-10-13
PCT/CA2000/001233 WO2001027630A2 (en) 1999-10-13 2000-10-13 Methods to identify compounds that modulate neuronal activity

Publications (2)

Publication Number Publication Date
JP2003511087A true JP2003511087A (ja) 2003-03-25
JP2003511087A5 JP2003511087A5 (https=) 2007-12-06

Family

ID=22571069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001530589A Pending JP2003511087A (ja) 1999-10-13 2000-10-13 ニューロンの活性を調節する化合物を同定する方法

Country Status (9)

Country Link
US (1) US6531288B1 (https=)
EP (1) EP1230551B1 (https=)
JP (1) JP2003511087A (https=)
AT (1) ATE312350T1 (https=)
AU (1) AU7896700A (https=)
CA (1) CA2385907A1 (https=)
DE (1) DE60024664T2 (https=)
ES (1) ES2253263T3 (https=)
WO (1) WO2001027630A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296925A1 (en) * 2002-11-01 2004-06-07 Leucadia Technologies, Inc. Displacement sandwich immuno-pcr
US20050266524A1 (en) * 2003-12-03 2005-12-01 Bulla Lee A Beta integrin gene and protein
EP2302078B1 (en) * 2004-11-03 2015-07-15 Iris Molecular Diagnostics, Inc. Microbubbles for affinity concentration
DK1842226T3 (da) * 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
CN103884840A (zh) * 2008-02-21 2014-06-25 艾瑞斯国际有限公司 早期确定前列腺癌治疗后复发的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004822A1 (en) * 1993-08-11 1995-02-16 The Salk Institute Biotechnology/Industrial Associates, Inc. Human calcium channel compositions and methods using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5623051A (en) 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
JPH09299092A (ja) * 1996-03-12 1997-11-25 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004822A1 (en) * 1993-08-11 1995-02-16 The Salk Institute Biotechnology/Industrial Associates, Inc. Human calcium channel compositions and methods using them

Also Published As

Publication number Publication date
DE60024664T2 (de) 2006-07-06
US6531288B1 (en) 2003-03-11
ATE312350T1 (de) 2005-12-15
WO2001027630A2 (en) 2001-04-19
CA2385907A1 (en) 2001-04-19
AU7896700A (en) 2001-04-23
ES2253263T3 (es) 2006-06-01
EP1230551A2 (en) 2002-08-14
WO2001027630A3 (en) 2001-12-06
DE60024664D1 (de) 2006-01-12
EP1230551B1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
Fog et al. Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport
Hay et al. CGRP and its receptors
Feng et al. Homer regulates gain of ryanodine receptor type 1 channel complex
Matsuda et al. Phosphorylation of serine‐880 in GluR2 by protein kinase C prevents its C terminus from binding with glutamate receptor‐interacting protein
Gao et al. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits
Kanning et al. Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability
Norregaard et al. Delineation of an endogenous zinc‐binding site in the human dopamine transporter
Garcia et al. SAP90 binds and clusters kainate receptors causing incomplete desensitization
Doll et al. Agonist‐selective patterns of µ‐opioid receptor phosphorylation revealed by phosphosite‐specific antibodies
Jockers et al. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?
Trester-Zedlitz et al. Mass spectrometric analysis of agonist effects on posttranslational modifications of the β-2 adrenoceptor in mammalian cells
Altier et al. Trafficking of L-type calcium channels mediated by the postsynaptic scaffolding protein AKAP79
Steiner et al. Reticulon 1‐C/neuroendocrine‐specific protein‐C interacts with SNARE proteins
Andrews et al. Interaction of calmodulin with the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex
Fukuda et al. Synaptotagmin IX regulates Ca2+-dependent secretion in PC12 cells
Artalejo et al. Specific role for the PH domain of dynamin‐1 in the regulation of rapid endocytosis in adrenal chromaffin cells
Koshimizu et al. Complex formation between the vasopressin 1b receptor, β-arrestin-2, and the μ-opioid receptor underlies morphine tolerance
Garelja et al. Pharmacological characterisation of mouse calcitonin and calcitonin receptor‐like receptors reveals differences compared with human receptors
Narayan et al. Mu opioids induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, Oprm1
Sachdev et al. Highly biased agonism for GPCR ligands via nanobody tethering
Birdsong et al. Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure
Chaumont et al. Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1
Lau et al. Differential regulation of serotonin transporter cell surface expression
AU2002355997B2 (en) Sodium channel regulators and modulators
Bachert et al. A sensor of protein O‐glycosylation based on sequential processing in the Golgi apparatus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110323